Profile data is unavailable for this security.
About the company
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).
- Revenue in USD (TTM)177.64m
- Net income in USD-383.45m
- Incorporated2008
- Employees380.00
- LocationTravere Therapeutics Inc3611 Valley Centre Dr, Suite 300SAN DIEGO 92130United StatesUSA
- Phone+1 (760) 260-8600
- Fax+1 (302) 645-1280
- Websitehttps://travere.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cullinan Therapeutics Inc | 0.00 | -142.16m | 1.05bn | 85.00 | -- | 1.60 | -- | -- | -3.10 | -3.10 | 0.00 | 11.34 | 0.00 | -- | -- | 0.00 | -23.96 | -12.37 | -24.85 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Pharvaris NV | 0.00 | -127.35m | 1.05bn | 82.00 | -- | 2.84 | -- | -- | -2.67 | -2.67 | 0.00 | 6.88 | 0.00 | -- | -- | 0.00 | -42.13 | -36.09 | -45.04 | -38.27 | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
| Vir Biotechnology Inc | 78.88m | -483.04m | 1.06bn | 587.00 | -- | 0.7393 | -- | 13.44 | -3.58 | -3.58 | 0.5838 | 10.50 | 0.0403 | -- | -- | 134,373.10 | -24.69 | -0.6081 | -26.90 | -0.7192 | 98.80 | -- | -612.40 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Praxis Precision Medicines Inc | 1.77m | -123.74m | 1.09bn | 82.00 | -- | 2.61 | -- | 616.73 | -10.26 | -10.26 | 0.1393 | 23.60 | 0.0062 | -- | -- | 21,597.56 | -43.07 | -74.04 | -46.74 | -85.12 | -- | -- | -6,987.01 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| CARGO Therapeutics Inc | 0.00 | -147.71m | 1.09bn | 116.00 | -- | 2.51 | -- | -- | -3.47 | -3.47 | 0.00 | 9.51 | 0.00 | -- | -- | 0.00 | -53.66 | -- | -59.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -82.83m | 1.10bn | 52.00 | -- | 3.59 | -- | -- | -1.93 | -1.93 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -26.91 | -42.26 | -28.35 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Phathom Pharmaceuticals Inc | 9.92m | -297.11m | 1.10bn | 452.00 | -- | -- | -- | 110.74 | -5.13 | -5.13 | 0.1717 | -3.99 | 0.0339 | 1.72 | -- | 21,942.48 | -101.68 | -83.26 | -115.19 | -93.77 | 80.15 | -- | -2,995.68 | -135,982.00 | 6.44 | -5.74 | 1.86 | -- | -- | -- | -1.96 | -- | -- | -- |
| AnaptysBio Inc | 30.47m | -170.12m | 1.16bn | 117.00 | -- | 106.86 | -- | 38.12 | -6.34 | -6.34 | 1.14 | 0.3601 | 0.0645 | -- | 5.00 | 260,453.00 | -36.02 | -18.08 | -39.45 | -18.96 | -- | -- | -558.25 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Prothena Corporation PLC | 217.25m | -50.92m | 1.16bn | 173.00 | -- | 2.00 | -- | 5.35 | -1.01 | -1.01 | 3.94 | 10.82 | 0.318 | -- | 829.18 | 1,255,757.00 | -7.45 | -14.20 | -8.16 | -15.11 | -- | -- | -23.44 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Travere Therapeutics Inc | 177.64m | -383.45m | 1.16bn | 380.00 | -- | 76.77 | -- | 6.55 | -4.99 | -1.88 | 2.31 | 0.1981 | 0.2759 | 0.7613 | 7.92 | 467,484.20 | -59.56 | -36.95 | -74.41 | -44.77 | 94.70 | 95.92 | -215.85 | -165.79 | 2.99 | -- | 0.9615 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Arcutis Biotherapeutics Inc | 132.06m | -198.76m | 1.19bn | 296.00 | -- | 6.34 | -- | 8.98 | -2.18 | -2.18 | 1.36 | 1.60 | 0.3451 | 0.8334 | 4.36 | 446,155.40 | -51.93 | -65.64 | -58.68 | -71.72 | 92.32 | -- | -150.51 | -1,513.03 | 8.19 | -5.94 | 0.5223 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Cogent Biosciences Inc | 0.00 | -227.05m | 1.20bn | 164.00 | -- | 4.63 | -- | -- | -2.48 | -2.48 | 0.00 | 3.41 | 0.00 | -- | -- | 0.00 | -55.22 | -49.53 | -60.02 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Relay Therapeutics Inc | 35.21m | -322.83m | 1.21bn | 304.00 | -- | 1.47 | -- | 34.49 | -2.52 | -2.52 | 0.277 | 5.11 | 0.0406 | -- | -- | 109,003.10 | -37.22 | -28.55 | -39.91 | -29.54 | -- | -- | -916.92 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Tyra Biosciences Inc | 0.00 | -80.88m | 1.29bn | 49.00 | -- | 3.42 | -- | -- | -1.69 | -1.69 | 0.00 | 7.13 | 0.00 | -- | -- | 0.00 | -25.18 | -- | -25.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Travere Therapeutics Inc's reporting currency: US Dollar USD
63.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Jun 2024 | 7.50m | 9.81% |
| Deep Track Capital LPas of 30 Jun 2024 | 7.37m | 9.64% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 6.50m | 8.50% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 6.16m | 8.06% |
| Rock Springs Capital Management LPas of 30 Jun 2024 | 4.48m | 5.86% |
| Macquarie Investment Management Business Trustas of 30 Jun 2024 | 4.37m | 5.71% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 3.51m | 4.59% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 3.34m | 4.37% |
| Millennium Management LLCas of 30 Jun 2024 | 2.95m | 3.86% |
| Assenagon Asset Management SA (Germany)as of 30 Jun 2024 | 2.21m | 2.90% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
